

Професор д-р Людмила Боянова Георгиева, дмн



Професор в Катедра медицинска микробиология, Медицински факултет на медицински университет-София.

E-mail: boyanova_lbg@medfac.mu-sofia.bg и l.boyanova@hotmail.com

Телефон: (3592) 9172730

Образование и професионален път

- Висше медицинско образование (медицина) с отличен успех (Медицинска академия-София) през 1985 г.
- Специалност по микробиология през 1989 г.
- Асистент (от 1985 г.); старши асистент (от 1991 г.); главен асистент (от 1994 г.) в Катедра микробиология, Медицински университет-София.
- Завеждащ Лаборатория анаеробни и микроаерофилни бактерии в Катедрата (от 1994 г.).
- Доцент по Микробиология в Катедрата (от 2002 г.).
- Професор в Катедра медицинска микробиология, МУ-София от 2012 г.
- Специализира във Франция- Universite Bordeaux 2, Bordeaux (1990-1991 г.) и в САЩ- Washington University, Saint Louis, Missouri (1994 г.).
- Защитава дисертация за придобиване на научната и образователна степен (ОНС) „доктор“ на тема „*Helicobacter pylori* в гастроудоденалната патология - микробиологични проучвания и връзка с терапевтичния подход“ през 1996 г. и
- Дисертационен труд за присъждане на ОНС „Доктор на медицинските науки“ (научна специалност 01.06.12, микробиология) на тема „*Helicobacter pylori* инфекцията у нас – разпространение, диагностика и насоки за терапия“ през 2009 г.

Преподавателска дейност:

- Лекции по микробиология на студенти медици, стоматолози и фармацевти на български и английски език; лекции по СДО в основни и тематични курсове на Катедра микробиология и курсове на гастроентеролози и инфекционисти.
- Съръководител на дисертационните разработки на двама успешно защитили докторанти.
- Сътрудничество с колеги от Франция, Португалия и Колумбия.

Научна дейност и трудове:

- Автор/съавтор в 221 статии, монографии и учебни помагала, от тях 125 в чужбина.
- Общо 113 статии в международни статии, 110 от тях с импакт фактор, 78 статии у нас, редактор и автор на 7 глави от чуждестранна монография и 13 глави от монографии у нас. Импакт факторът на публикациите над 300.
- Общо 2767 цитирания на публикациите, повечето (2682) в чуждестранни трудове.
- Девет участия в написване на учебници и ръководства.
- Ръководител/участник в 43 научноизследователски проекти.
- Експертна и рецензионна активност: като Associate Editor в списание Anaerobe на Elsevier отговорник за 71 международни ръкописа. Рецензент на 332 ръкописа за международни медицински списания, повечето с импакт фактор.
- Общо 41 участия като рецензент на научноизследователски проекти и в научни журита у нас.

НАГРАДИ И ОТЛИЧИЯ

- **Наградата “Академик д-р Димитър Ораховац” на Медицински Факултет-София** за високи постижения в научно-изследователската и преподавателска дейност. 15.03. 2006 г. (Награда за значителни приноси в научно-изследователската и преподавателска дейност в областта на фундаменталните науки
- **Награда Питагор на Министерството на образованието, младежта и науката** за утвърден учен в областта на биомедицинските науки. 2013 г.
- **Грамота на Медицинския Колеж „Йорданка Филаретова“ на Медицинския университет-София** за активна и творческа учебно-преподавателска дейност. 2005 г.
- **Отличие като рецензент (Certificate of excellence in Reviewing for 2013)**. Awarded by **Elsevier-Diagnostic Microbiology & Infectious disease** in recognition of an outstanding contribution to the quality of the journal. (Prof. Mark Holodniy, главен редактор на списанието и Fiona Macnab) 2014 г.
- **Отличие като рецензент (Certificate of outstanding contribution in Reviewing)**. Awarded by **Elsevier-International journal of antimicrobial agents** (The Editors). 2015 г.
- **Отличие като рецензент (Certificate of outstanding contribution in Reviewing)** Awarded by **Elsevier-Diagnostic Microbiology & Infectious disease** in recognition of the contributions made to the quality of the journal) 2018.
- Писмо за **Отличие като рецензент** от prof. Elisabeth Nagy, главен редактор на списание Anaerobe (Elsevier), 2020 г.
- Наградата „**SIGNUM LAUDIS PRO SCIENTIAE MERITIS**” на МУ-София за научна разработка за 2018-2019 год. на 11/11/2021 г.
- През 2021 г. **Stanford University** класира проф. Боянова в **първите 2% на най-влиятелните учени в света** през предходната година.
- Награден знак ПАНАЦЕЯ за особени приноси при реализацията на преподаването, научноизследователската и експертна дейност в медико-биологична област.
7.04.2022
Award sigh PANACEA for special contributions to realization of teaching, research and expert activity in medical biological field. April 7, 2022.

Членство в професионални организации:

- Член на Експертната комисия по микробиология на Министерството на здравеопазването (от 2019 г.).

- ESGAI на ESCMID (от 2020 г.),
- Research Gate,
- European Society of Chemotherapy (ESC, 2003),
- Българско дружество по медицинска микробиология-БДММ,
- Български лекарски съюз,
- Българска педиатрична асоциация (2011 г.),
- Съюз на учените в България

Езикови познания:

Владее английски, френски и испански езици и ползва руски език.

Област, в която работи:

- Завеждащ Лаборатория по анаеробни и микроаерофилни бактерии към Катедрата.
- Проучвания на *Helicobacter pylori* и свързаните инфекции.
- Координатор за България в Паневропейското проучване Pan-European Registry on *H. pylori* Management (HP-EuReg).
- Проучвания на облигатните анаеробни бактерии и свързаните инфекции.
- Проучвания на *Campylobacter* spp., бактерии от разред *Enterobacterales* и на др. видове.
- Направленията включват характеристика, диагностика, вирулентност, честота и еволюция на антибиотичната резистентност и множествената резистентност на изследваните бактерии и оптимизиране на терапевтичния подход на свързаните инфекции.
- Associate Editor в списанието *Anaerobe* на Elsevier.

Научни интереси:

- *Helicobacter pylori* инфекцията - автор/съавтор на най-много публикации в международни списания от български автори по тази тема, заради което е избрана за координатор за България в Паневропейското проучване Pan-European Registry on *H. pylori* Management (HP-EuReg).
- Проучване на облигатните анаеробни бактерии, заради активността си е избрана за Associate Editor в списанието *Anaerobe* на Elsevier.
- Гени за вирулентност и резистентност на *H. pylori* и анаеробни бактерии.
- Действие на пробиотиците и различни други неантибиотични следства.
- Множествена резистентност на *H. pylori* и анаеробните бактерии.
- Микробна ендокринология- действие на стрес хормоните върху бактериите.

Представителни научни публикации в международни медицински, повечето от които с импакт фактор (2012-2022 г.)

1. Markovska R, Boyanova L, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori oipA* genetic diversity and its associations with both disease and *cagA*, *vacA* s, m and i alleles among Bulgarian patients. *Diagn Microbiol Infect Dis*. 2011;71(4):335-340. (IF₂₀₁₂ 2,528)
2. Boyanova L, Mitov I. Coadministration of probiotics with antibiotics: why, when and for how long? *Expert Rev Anti Infect Ther*. 2012; 10(4):407-409. (IF₂₀₁₃ 3,063)
3. Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis. A Bulgarian study. *J Med Microbiol*. 2012;61(Pt 1):85-93. (IF₂₀₁₃ 2,266)

4. Boyanova L, Mitev A, Gergova G, Mateev G, Mitov I. High prevalence and resistance rates to antibiotics in anaerobic bacteria in specimens from patients with chronic balanitis. *Anaerobe*. 2012; 18: 414-416. (IF₂₀₁₃ 2,364)
5. Yordanov D, Boyanova L, Markovska R, Gergova G, Mitov I. Significance of *Helicobacter pylori vacA* intermediate region genotyping-a Bulgarian study. *Diagn Microbiol Infect Dis* 2012; 74(3): 253-257. (IF₂₀₁₃ 2,568)
6. Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients. Rising concerns. *Expert Rev. Anti Infect. Ther.* 2013; 11(4): 411-420. (IF₂₀₁₄ 3,461)
7. Boyanova L, Ilieva J, Gergova G, Evstatiev I, Nikolov R, Mitov I. Living in Sofia is associated with a risk for antibiotic resistance in *H. pylori*. A Bulgarian study. *Folia Microbiol (Praha)*. 2013; 58(6):587-591. (IF₂₀₁₅ 1,335)
8. Boyanova L, Panov V, Yordanov D, Gergova G, Mitov I. Characterization of oral *Helicobacter pylori* strain by 4 methods. *Diagn Microbiol Infect Dis* 2013; 77 (4): 287-288. (IF₂₀₁₅ 2,45)
9. Markovska R, Schneider I, Stoeva T, Bojkova K, Boyanova L, Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing *Klebsiella pneumoniae* in Bulgaria. *Diagn Microbiol Infect Dis*. 2013;77(3): 252-253. (IF₂₀₁₅: 2,45)
10. Boyanova L. Comparative evaluation of the activity of plant infusions against *Helicobacter pylori* strains by three methods. *World J Microbiol Biotechnol*. 2014; 30(5): 1633-1637. (IF₂₀₁₅ 1,658)
11. Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. *Helicobacter pylori* susceptibility to fosfomycin, rifampin and five usual antibiotics for *H. pylori* eradication. *Diagn Microbiol Infect Dis* 2014; 79:358-361. (IF₂₀₁₆ 2,401)
12. Boyanova L, Sabov R, Kolarov R, Mitov I. Chronic odontogenic osteomyelitis and facial actinomycosis of six-month duration. *JMM Case Reports*. 2014 doi 10.1099/jmmcr.0.000729
13. Boyanova L, Kolarov R, Mitov I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. *Anaerobe*. 2015, 31: 4-10. (IF₂₀₁₆ 2,278)
14. Boyanova L. Susceptibility of anaerobes to fusidic acid and fosfomycin. *Int J Antimicrob Agents*. 2015; 45(5):560-561. (IF₂₀₁₅ 4,307)
15. Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of *Helicobacter pylori* infection. *Diagn Microbiol Infect Dis*. 2015; 82(1):85-86. Most Downloaded Diagnostic Microbiology and Infectious Disease Articles in April 2015 <http://www.journals.elsevier.com/diagnostic-microbiology-and-infectious-disease/most-downloaded-articles/> (IF₂₀₁₆ 2,401)
16. Boyanova L, Kolarov R, Mateva L, Markovska R, Mitov I. Actinomycosis- a frequently forgotten disease. *Future Microbiol*. 2015; 10(4): 613–628. (IF₂₀₁₆ 3,374)
17. Kotsilkov K, Popova C, Boyanova L, Setchanova L, Mitov I. Comparison of culture method and real-time PCR for detection of putative periodontopathogenic bacteria in deep periodontal pockets. *Biotechnol. Equip.* 2015; http://www.tandfonline.com/doi/abs/10.1080/13102818.2015.1058188#.Vco9c_ (IF₂₀₁₆ 1,059)
18. Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing *Klebsiella pneumoniae* in Bulgaria. *APMIS*. 2015; 123(10):887-894. (IF₂₀₁₆ 1,795)
19. Boyanova L, Yaneva P, Gergova G, Lazarova E, Mitov I. Current antibiotic resistance patterns in *Helicobacter pylori* strains from untreated children. *C. R. Acad. Bulg. Sci.* 2015; 68(11): 1449-1456 . (IF₂₀₁₆ 0.251)

20. Boyanova L, Evstatiev I, Gergova G, Yaneva P, Mitov I. Linezolid susceptibility in *Helicobacter pylori*, including strains with multidrug resistance. *Int J Antimicrob Agents*. 2015; 46(6):703-706. (IF₂₀₁₆ 4,307)
21. Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. *Helicobacter pylori* resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. *Infect Dis (Lond)*. 2016; 48(1): 56-62. (IF₂₀₁₅ 1,366)
22. Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I. Clarithromycin resistance mutations in *Helicobacter pylori* in association with virulence factors and antibiotic susceptibility of the strains. *Microb Drug Resist*. 2016; 22(3): 227-232. (IF₂₀₁₆ 2,306)
23. Boyanova L, Ilieva J, Gergova G, Mitov I. Levofloxacin susceptibility testing against *Helicobacter pylori*: evaluation of a modified disk diffusion method compared to E test. *Diagn Microbiol Infect Dis*. 2016; 84(1): 55-56. (IF₂₀₁₆ 2,401)
24. Boyanova L, Evstatiev I, Yordanov D, Markovska R, Mitov I. Three unsuccessful treatments of *Helicobacter pylori* infection by a highly virulent strain with quadruple antibiotic resistance. *Folia Microbiol (Praha)*. 2016; 61(4): 307-310. (IF₂₀₁₆ 1,521)
25. Boyanova L, Markovska R, Mitov I. Review article: virulence arsenal of the most pathogenic species among the Gram-positive anaerobic cocci, *Finegoldia magna*. *Anaerobe*. 2016; 42:145-151. (IF₂₀₁₆ 2,278)
26. Yordanov D, Boyanova L, Markovska R, Ilieva J, Andreev N, Gergova G, Mitov I. *Helicobacter pylori* seroprevalence in Bulgaria over 18 years and anti-CagA seroprevalence. *C R Acad Bulg Sci*. 2016; 69(12): 1651-1658. (IF₂₀₁₆ 0,251)
27. Markovska R, Stoeva T, Boyanova L, Stankova P, Pencheva D, Kaneva R, Mitev V, Mitov I. Isolation of *Escherichia coli* ST131 producing KPC-2 in Bulgaria. *Infect Dis (Lond)*. 2017; 49(5): 429-431. (IF₂₀₁₅ 1,366)
28. Boyanova L. Stress hormone epinephrine (adrenaline) and norepinephrine (noradrenaline) effects on the anaerobic bacteria. *Anaerobe*. 2017; 44:13-19. (IF₂₀₁₆ 2,278)
29. Yordanov D, Boyanova L, Markovska RD, Ilieva J, Andreev N, Gergova G, Mitov IG. Influence of dietary factors on *Helicobacter pylori* and CagA seroprevalence in Bulgaria. *Gastroenterol Res Pract*. 2017; 2017: Article ID 9212143, doi:10.1155/2017/9212143 <https://www.hindawi.com/journals/grp/2017/9212143/> (IF₂₀₁₆ 1,863)
30. Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary *Helicobacter pylori* resistance in elderly patients over 20 years. A Bulgarian study. *Diagn Microbiol Infect Dis*. 2017; 88(3): 264-267. (IF₂₀₁₆ 2,401)
31. Markovska R, Stoeva T, Boyanova L, Stankova P, Pencheva D, Keuleyan E, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Kaneva R, Mitov I. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing *K. pneumoniae* isolates. *Diagn Microbiol Infect Dis*. 2017; 89(4): 310-313. (IF₂₀₁₆ 2,401)
32. Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. Bacteriocin-like inhibitory activities of seven *Lactobacillus delbrueckii* subspecies *bulgaricus* strains against antibiotic susceptible and resistant *Helicobacter pylori* strains. *Lett Appl Microbiol*. 2017;65(6): 469-474. (IF₂₀₁₆ 1,575)
33. Boyanova L. Direct Gram staining and its various benefits in the diagnosis of bacterial infections. *Postgrad Med*. 2018; 130(1): 105-110. (IF₂₀₁₆ 2,062)
34. Markovska R, Boyanova L, Yordanov D, Stankova P, Gergova G, Mitov I. Status of *Helicobacter pylori* *cag* pathogenicity island (*cagPAI*) integrity and significance of its individual genes. *Infect Genet Evol*. 2018; 59: 167-171. (IF₂₀₁₆ 2,885)
35. Nagy E, Boyanova L, Justesen US; ESCMID Study Group of Anaerobic Infections. How to isolate, identify and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories? *Clin Microbiol Infect*. 2018; 24(11): 1139-1148. (IF₂₀₁₆ 5,292)

36. Boyanova L, Koumanova R, Hadzhiyski P, Gergova G, Markovska R, Yordanov D, Mitov I. *Helicobacter pylori* infection in Bulgarian pediatric patients. C R Acad Bulg Sci. 2018; 71(7): 971-977. (IF₂₀₁₇ 0,270)
37. Yordanov D, Boyanova L, Markovska R, Hadzhiyski P, Gergova G, Mitov I. Seroprevalence of *Helicobacter pylori* IgG and CagA IgG in Bulgarian children. C R Acad Bulg Sci. 2018; 71(8): 1124-1129. (IF₂₀₁₇ 0,270)
38. Markovska R, Keuleyan E, Stankova P, Boyanova L, Stoeva T, Murjeva M, Sredkova M, Ivanova D, Lazarova G, Nedelcheva G, Mitov I. Antimicrobial susceptibility of clinically significant isolates of *Klebsiella pneumoniae* and *Escherichia coli* resistant to cephalosporins third generation collected from patients in Bulgarian hospitals. C R Acad Bulg Sci. 2018; 71(8): 1130-1138. (IF₂₀₁₆ 0,251)
39. Boyanova L, Markovska R, Mitov I. *Helicobacter pylori* growth stimulation by adrenaline detected by two methods. Diagn Microbiol Infect Dis. 2019; 93(1): 30-32. (IF₂₀₁₉ 2,803)
40. Boyanova L, Hadzhiyski P, Markovska R, Yaneva P, Yordanov D, Gergova G, Mitov I. Prevalence of *Helicobacter pylori* is still high among symptomatic Bulgarian children. Acta Microbiol Immunol Hung. 2019; 66(2): 255-260. (IF₂₀₁₇ 1,107)
41. Markovska R, Stoeva T, Boyanova L, Stankova P, Schneider I, Keuleyan E, Mihova K, Murdjeva M, Sredkova M, Lesseva M, Nedelcheva G, Petrova A, Ivanova D, Lazarova G, Kaneva R, Mitov I. Multicentre investigation of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing *K. pneumoniae*. Infect Genet Evol. 2019; 69: 61-67. (IF₂₀₁₇ 2,545)
42. Boyanova L, Markovska R, Hadzhiyski P, Yordanov D, Yaneva P, Mitov I. Recurrent *Clostridioides (Clostridium) difficile* infection in a patient suffering from inflammatory bowel disease and benefits of resistotyping. Diagn Microbiol Infect Dis. 2019; 94(4): 334-336. (IF₂₀₁₉ 2,803)
43. Markovska R, Stoeva T, Dimitrova D, Boyanova L, Stankova P, Mihova K, Mitov I. Quinolone resistance mechanisms among third generation cephalosporin resistant isolates of *Enterobacter* spp. in a Bulgarian university hospital. Infect Drug Resist. 2019; 12: 1445–1455. (IF₂₀₁₇ 3,779)
44. McNicholl AG, O'Morain CA, Megraud F, Gisbert JP; As Scientific Committee of the Hp-Eureg on Behalf of the National Coordinators (including Boyanova L). Protocol of the European Registry on the management of *Helicobacter pylori* infection (Hp-EuReg). Helicobacter. 2019; 24(5): e12630, including Appendix S1. Local Coordinators (Lyudmila Boyanova). (IF₂₀₁₈ 3,352)
45. Boyanova L, Kalvatchev N, Yordanov D, Hadzhiyski P, Markovska R, Gergova G, Mitov I. *Clostridioides (Clostridium) difficile* carriage in asymptomatic children since 2010: a narrative review. Biotechnol Biotech Eq. 2019; 33 (1): 1228-1236. (IF₂₀₁₈ 1,227)
46. Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in *Helicobacter pylori*: current state and future directions. Expert Rev Clin Pharmacol. 2019; 12(9): 909-915. (IF₂₀₁₈ 2,776)
47. Boyanova L, Markovska R, Mitov I. Multidrug resistance in anaerobes. FutureMicrobiol. 2019; 14(12): 1055–1064. (IF₂₀₁₈ 2,746)
48. Marteva-Proevska Y, Velinov Tsv, Markovska R, Dobrikova D, Pavlov I, Boyanova L, Mitov I. High level of colistin resistant Gram-negative bacteria in a University Hospital in Bulgaria. C R Acad Bulg Sci. 2019 in press (IF₂₀₁₉ 0,343)
49. Markovska R, Stoeva T, Stankova P, Boyanova L, Dimitrova D, Gergova R, Mitov I. First report of *Enterobacter asburiae* isolate, producing NDM-1 and a novel ACT-68 enzyme in Bulgaria. Infect Dis (Lond). 2019; 51(8): 627-629. (IF₂₀₁₈ 2,191)

50. Boyanova L, Markovska R, Medeiros J, Gergova G, Mitov I. Delafloxacin against *Helicobacter pylori*, a potential option for improving the eradication success? *Diagn Microbiol Infect Dis.* 2020; 96(4): 114980. (IF₂₀₁₉ 2,803)
51. Boyanova L, Yordanov D, Ouzounova-Raykova V, Markovska R, Marteva-Proevska Y, Mitov I. Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates. *Anaerobe.* 2020; 62: 102150. (IF₂₀₂₀ 3,331)
52. Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of *Helicobacter pylori* infection: a review of recent data. *Future Microbiol.* 2020; 15:1185-1196. (IF₂₀₁₉ 2,907)
53. Boyanova L, Hadzhiyski P. *Helicobacter pylori* infection is associated with anemia, weight loss or both conditions among Bulgarian children. *Acta Microbiol Immunol Hung.* 2020; 67(4): 239-242. (IF₂₀₁₉ 0,864)
54. Nyssen OP, Pérez-Aisa A, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Jurecic NB, Huguet JM, Alcaide N, Voynovan I, Bote JMB, Modolell I, Lasala JP, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Pinto RM, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, ... *Helicobacter pylori* first-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on *H. pylori* management (Hp-EuReg). *Helicobacter.* 2020; 25(3): e12686. (IF₂₀₂₀ 5,753)
55. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on *Helicobacter pylori* management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. *Gut.* 2021; 70(1): 40-54. (IF₂₀₂₁ 31,793)
56. Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European *Helicobacter pylori* Antimicrobial Susceptibility Testing Working Group. Collaborators: European *Helicobacter pylori* Antimicrobial Susceptibility Testing Working Group: Athanasios Makristathis, Lyudmila Boyanova, Ante Tonkic, Marija Tonkic, Leif Andersen, Benjamin Blumel, Erick Glocker, Ina Tammer, Alexander Link, Sebastian Suerbaum, Karl Dichtl, Andreas Mentis, Beatriz Marintez-Gonzales, Sinead Smith, Deirdre McNamara, Maria Pina Dore, Rosa Monno, Antonio Lippolis, Dace Rudzite, Marcis Leja, Juozas Kupcinskas, Kjetil K Melby, Grazyna Gosciniak, Tomasz M Karpinski, Monica Oleastro, Samo Jeverica, Xavier Calvet, Maria José Ramirez-Lázaro, Milagrosa Montes Ros, Ana Morilla, Sjoukje Boonstra, Peter M Schneeberger. *Helicobacter pylori* resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. *Gut.* 2021 Apr 9: gutjnl-2021-324032. (IF₂₀₂₁ 31,793)
57. Gergova R, Muhtarova A, Boyanova L, Markovska R. Distribution of *msr(D)*, *mef(A/E)*, *emm* genotypes and virulence profiles among Bulgarian macrolide resistant *Streptococcus pyogenes* isolates. *C R Acad Bulg Sci (Proceedings of the Bulgarian Academy of Sciences),* 2021; 74(11):1673-1681. (IF₂₀₂₁ 0,329)
58. Markovska R, Stankova P, Stoeva T, Ivanova D, Pencheva D, Kaneva R, Boyanova L. Fecal carriage and epidemiology of extended-spectrum beta-lactamase/carbapenemases

- producing *Enterobacterales* isolates in Bulgarian hospitals. *Antibiotics*. 2021; 10(6):747. <https://doi.org/10.3390/antibiotics10060747> (IF₂₀₂₁ 5,222)
59. Boyanova L, Hadzhiyski P, Markovska R. Review – Epidemiology of *Helicobacter pylori* infection. *Microb Health Dis* 2021; 3: e543. In: *The Year in Helicobacter 2021*. DOI: 10.26355/mhd_20218_543
 60. Boyanova L, Marteva-Proevska Y, Gergova R, Markovska R. *Gardnerella vaginalis* in urinary tract infections, are men spared? *Anaerobe*. 2021, 72: 102438. doi: <https://doi.org/10.1016/j.anaerobe.2021.102438> (IF₂₀₂₁: 2.837)
 61. Caldas M, Pérez-Aisa Á, Tepes B, Keco-Huerga A, Bujanda L, Lucendo AJ, Rodrigo L, Vaira D, Fernández-Salazar L, Huguet JM, Pérez-Lasala J, Jurecic NB, Fadeenko G, Barrio J, Areia M, Ortuño J, Pellicano R, Leja M, Molina-Infante J, Bogomolov P, Alekseenko S, Domínguez-Cajal M, Gómez-Camarero J, Ntouli V, Martínez-Domínguez SJ, Ruiz-Zorrilla R, Núñez O, Sarsenbaeva AS, Almela P, Phull P, Espada M, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; the Hp-EuReg Investigators (including Boyanova L). The Role of Statins on *Helicobacter pylori* eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). *Antibiotics (Basel)*. 2021;10(8):965. doi: 10.3390/antibiotics10080965. (IF₂₀₂₁ 5,222)
 62. Boyanova L, Marteva-Proevska Y, Markovska R, Yordanov D, Gergova R. Urinary tract infections: Should we think about the anaerobic cocci? *Anaerobe*, 2022, Available online 4 January 2022, 102509 <https://doi.org/10.1016/j.anaerobe.2021.102509> (IF₂₀₂₁:2.837)
 63. Boyanova L, Hadzhiyski P, Markovska R, Gergova R. Investigation of multidrug-resistant *Helicobacter pylori* in pediatric patients: A Bulgarian study and literature data. *Acta Microbiol Immunol Hung*. 2022. doi: 10.1556/030.2022.01682. (IF₂₀₂₁: 1.811)
 64. Nyssen OP, Vaira D, Pérez Aisa Á, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanás A, Lucendo AJ, Bujanda L, Ortuño J, Barrio J, Huguet JM, Voynovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupčinskis J, Bordin D, Marcos-Pinto R, Lerand F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovský L, Beglinger C, Douberis M, Marlicz W, Goldis A, Tonkić A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP; European Registry on Helicobacter pylori Management Hp-EuReg Investigators. Empirical Second-Line Therapy in 5,000 Patients of the European Registry on *Helicobacter pylori* Management (Hp-EuReg). *Clin Gastroenterol Hepatol*. 2021:S1542-3565(21)01349-5. doi: 10.1016/j.cgh.2021.12.025. (IF₂₀₂₁: 13.576)
 65. Boyanova L, Kandilarov N, Hadzhiyski P, Gergova R, Gergova G, Markovska R. Increase in amoxicillin resistance in *Helicobacter pylori* from Bulgarian patients over 15 years. *Diagn Microbiol Infect Dis*. 2022; 104: 115746. <https://doi.org/10.1016/j.diagmicrobio.2022.115746> (IF₂₀₂₁: 2,983)
 66. Gergova R, Tsitou V-M, Dimov SG, Boyanova L, Mihova K, Strateva T, Gergova I, Markovska R. Molecular epidemiology, virulence and antimicrobial resistance of Bulgarian methicillin resistant *Staphylococcus aureus* isolates. *Acta Microbiol Immunol Hung*. 2022, DOI: <https://doi.org/10.1556/030.2022.01766> (IF₂₀₂₁: 1.811)
 67. Markovska R, Marteva-Proevska Y, Velinov T, Pavlov I, Kaneva R, Boyanova L. Detection of different colistin resistance mechanisms among multidrug resistant *Klebsiella pneumoniae* isolates in Bulgaria. *Acta Microbiol Immunol Hung*. 2022 Jun 27. doi: <https://doi.org/10.1556/030.2022.01746> (IF₂₀₂₁: 1.811)
 68. Hadzhiyski P, Baycheva M, Shentova-Eneva R, Kofinova D, Markovska R, Mitov I, Boyanova L. Role of extended family for intrafamilial transmission of *Helicobacter pylori* infection in Bulgarian children. *C R Acad Bulg Sci*. 2021 in press (IF₂₀₂₀ 0,329)

69. Boyanova L, Markovska R, Mitov I, Gergova R. Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect? *Expert Rev Clin Pharmacol*. 2022 Aug 1. doi: 10.1080/17512433.2022.2108403. (IF₂₀₂₁ 4.108)